The Manufacturers Life Insurance Company Invests $743,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

The Manufacturers Life Insurance Company bought a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 31,309 shares of the company's stock, valued at approximately $743,000. The Manufacturers Life Insurance Company owned about 0.11% of LENZ Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock worth $2,929,000 after buying an additional 81,901 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of LENZ Therapeutics in the third quarter valued at about $246,000. SG Americas Securities LLC bought a new stake in LENZ Therapeutics during the third quarter worth about $107,000. Deerfield Management Company L.P. Series C acquired a new position in LENZ Therapeutics during the second quarter valued at approximately $300,000. Finally, Squarepoint Ops LLC bought a new position in LENZ Therapeutics in the second quarter valued at approximately $181,000. Institutional investors own 54.32% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Raymond James initiated coverage on LENZ Therapeutics in a research note on Friday, September 27th. They set an "outperform" rating and a $37.00 price objective on the stock. William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Finally, HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $35.40.

LENZ Therapeutics Trading Up 0.6 %

LENZ Therapeutics stock traded up $0.19 during mid-day trading on Friday, hitting $30.97. 85,418 shares of the company's stock traded hands, compared to its average volume of 135,035. LENZ Therapeutics, Inc. has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The firm has a 50 day simple moving average of $31.07 and a two-hundred day simple moving average of $24.44.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.09. During the same quarter last year, the firm posted ($1.33) EPS. Research analysts forecast that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.